- Latest news▼
-
15:32, April 26 ESCMID: New method of purifying the air with ultraviolet light could protect world from new pandemic
-
08:43, April 26 Enzymes that convert different blood groups into first group are discovered
-
19:41, April 25 Children’s Hospital Los Angeles and International Center of Professional Development Allergy/Immunology Conference
-
17:31, April 25 JAMA: patient grew long, curly eyelashes because of chemotherapy
-
11:08, April 25 Mpox epidemic declared in Republic of the Congo
-
08:31, April 25 OU: quitting smoking 4 times more likely to cure laryngeal cancer
-
01:20, April 25 Paralyzed man in China writes hieroglyphs using neural implants placed in his brain
-
15:11, April 24 Zombie deer disease possibly linked to hunters’ deaths
-
12:27, April 23 Appetite: Scientists found out the secret to the appeal of large portions of fast food
-
10:33, April 23 Scientists test new approach to fighting viruses
-
08:38, April 23 Ketamine may help with postpartum depression
-
22:12, April 22 Unhealthy amount of sugar found in baby food products of a well-known brand
-
19:41, April 22 Air pollution puts health of more than 1.6 billion workers globally at risk
-
17:25, April 22 Scientists found baked goods and lack of sleep to be more dangerous than alcohol
-
16:02, April 22 342 cases of measles recorded in Armenia so far in 2024
All materials
Pfizer's lymphoma drug successfully tested
The Pfizer company said on Tuesday its drug, Adcetris, extended survival in patients with the most common type of lymphoma in a late-stage study of the disease, Reuters reported.
Lymphoma is an oncological disease in which the lymphoid tissue is the source of a malignant tumor.
The New York-based drugmaker last year struck a deal to acquire Seagen and its targeted cancer therapies.
The company, which has US and Canadian commercialization rights for Adcetris, reported total sales of $46 million from the drug last year.
Pfizer said on Tuesday it plans to discuss with regulators a submission for approval to treat these patients.
A potential greenlight for Adcetris for the most common type of lymphoma will pave the way for the eighth approval for the drug and beef up an oncology portfolio that already has more than 25 approved therapies.
The combination therapy consisting of Adcetris and two other drugs was statistically significant compared to a placebo in extending survival in patients with lymphoma known as diffuse large B-cell lymphoma.
The trial tested 230 patients whose cancer does not express a protein known as CD30 and returns after a period of remission or does not respond to treatment.
The drug, when compared to a combination of two other drugs plus placebo, also showed improvements in both secondary study goals of progression-free survival, or how long before the disease begins to worsen.
It also showed improvements in overall response rate, or proportion of patients who have a partial or complete response to the therapy.
Follow NEWS.am Medicine on Facebook and Twitter
- Video
- Event calendar
- Children’s Hospital Los Angeles and International Center of Professional Development Allergy/Immunology Conference
- First Armenian-German Conference entitled “Heart Failure Spring School”
- Allogeneic bone marrow transplant in case of hematological malignancy performed in Armenia for first time
All materials
- Archive
- Most read
month
week
day
- Scientists found baked goods and lack of sleep to be more dangerous than alcohol 1054
- Next pandemic likely to be triggered by flu - scientists 1041
- 342 cases of measles recorded in Armenia so far in 2024 974
- Unhealthy amount of sugar found in baby food products of a well-known brand 920
- Air pollution puts health of more than 1.6 billion workers globally at risk 909
- Ketamine may help with postpartum depression 902
- Appetite: Scientists found out the secret to the appeal of large portions of fast food 896
- Scientists test new approach to fighting viruses 876
- Zombie deer disease possibly linked to hunters’ deaths 839
- Scientists develop new method to safely stimulate immune cells to fight cancer 837
- Cognitively stimulating jobs in midlife could lower dementia risk in old age, study finds 833
- Blood test can determine who is at risk of developing multiple sclerosis - scientists 831
- BrainStimulation: electrical brain stimulation alleviates anxiety and depression in the elderly 767
- Mpox epidemic declared in Republic of the Congo 638
- Paralyzed man in China writes hieroglyphs using neural implants placed in his brain 613
- Find us on Facebook
- Poll